REG - IQ-AI Limited - Reduced Gadolinium Approach Validated'

IQ-AIAnnouncement

08/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230908:nRSH7871La&default-theme=true

RNS Number : 7871L  IQ-AI Limited  08 September 2023

8 September 2023

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Reduced Gadolinium Approach Validated with IB Neuro on 1.5T MR Scanners

 

Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE:
IQAI), is pleased to announce the results of a study that validates IB Neuro's
processing of reduced-dose gadolinium-based contrast agent (GBCA) perfusion
studies on 1.5T scanners.

 

The multi-center study, led by Dr. Mark Shiroishi, MD, Assistant Professor of
Neuroradiology and Director of Neuro-Oncology Imaging at the Keck School of
Medicine of USC, is an extension of the foundational study published in April
2019 (Moving Towards a Consensus DSC-MRI Protocol:  Validation of A Low Flip
Angle Single Dose Option as a Reference Standard for Brain Tumors) that
validated the  use of a low-dose protocol for acquiring MRI perfusion data.
In the 2019 study, it was shown that 3T MRI data collected with 50% less GBCA
could provide perfusion maps comparable to the higher dose standard when
processed using IB Neuro.

 

IB Neuro has now been validated using this approach on 1.5T scanners.

 

Dynamic susceptibility contrast (DSC) MRI is the most common approach used to
measure brain tumor perfusion. Relative cerebral blood volume (rCBV) is the
most widely generated parameter map that provides important information
regarding tumor grade, prognosis, and treatment response. IB Neuro
automatically processes DSC data using its unique contrast leakage (of GBCA)
correction technology. It is the only platform that generates quantitative
output that can be directly compared across timepoints. This study also makes
IB Neuro the only platform proven to provide accurate perfusion maps under
low-dose conditions at both 1.5T and 3T MR scanners.

 

"IQ-AI and our collaborators around the world continue to make advancements
towards reducing GBCA consumption," said Trevor Brown, CEO of IQ-AI. "While
our patented artificial intelligence technology available in IB Zero G remains
in active development, this study provides an immediate option for cutting
GBCA by 50% on 1.5T and 3T scanners", Brown added.

 

"The study demonstrates that a single dose (no preload), low flip angle method
does not compromise image quality," said Dr. Mark Shiroishi, MD. "This is a
great added benefit for patients who may have concerns about GBCA risks, and
for administrators looking for opportunities to curtail operational expenses".

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

For further information, please contact:

 IQ-AI Ltd
 Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI
Limited, (LON: IQAI) (OTCQB: IQAIF) and focuses on delivering quantitative
imaging platforms and therapeutics that transform how clinicians diagnose and
treat patients more efficiently and effectively. For more information about
Imaging Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on Twitter, @IQAI_IB.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRUBVRROAUKRUR